NAGE

In the past six months, Niagen Bioscience's stock has been impacted by several events. The company reported Q1 2026 results that exceeded consensus estimates, with total net sales increasing 3% to $31.5 million and net income climbing to $6.3 million. Niagen Bioscience launched a clinician-directed telehealth platform for Niagen Plus, offering at-home injection kits to eligible U.S. patients. The company added Olympia Pharmaceuticals to its 503B Compounding Partner Network, diversifying its supply chain and expanding Niagen Plus offerings. Niagen Bioscience collaborated with the U.S. Pharmacopeia (USP) to establish the first-ever USP monograph for nicotinamide riboside chloride (NRCl), setting a quality benchmark for the ingredient. The company expanded its Niagen Plus clinical channel through a partnership with OneSpaWorld, making Niagen IV available in over 80 Medi-Spa clinics on luxury cruise ships. Niagen Bioscience pilot-launched Niagen's Nanocloud, its first skincare topical product, with strong early demand. The company completed the sale of its Analytical Reference Standards and Services segment to LGC Standards in an all-cash transaction, streamlining operations. The board approved a $20 million increase in the company's share repurchase program. As of May 10, 2026, the stock has experienced a 6.26% decline in the past 30 days and a 32.96% decline year-to-date. Over the past 12 months, the stock has lost 50.4% of its value. Roth Capital lowered its price target on NAGE from $13 to $12 in May 2026.